HCW Biologics Stock (NASDAQ:HCWB)
Previous Close
$1.97
52W Range
$1.52 - $41.20
50D Avg
$3.15
200D Avg
$5.99
Market Cap
$3.72M
Avg Vol (3M)
$108.83K
Beta
0.67
Div Yield
-
HCWB Company Profile
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
HCWB Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CELZ | Creative Medical Technology Holdings, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| APVO | Aptevo Therapeutics Inc. |
| NRSN | NeuroSense Therapeutics Ltd. |
| ACXP | Acurx Pharmaceuticals, Inc. |
| INAB | IN8bio, Inc. |
| ADIL | Adial Pharmaceuticals, Inc. |
| BCLI | Brainstorm Cell Therapeutics Inc. |
| APRE | Aprea Therapeutics, Inc. |
| BCDA | BioCardia, Inc. |